Analyst Ratings for Denali Therapeutics Inc. (DNLI)
DNLI Rating Summary
DNLI Price Target Summary
- Highest: $112.00 (Goldman Sachs)
- Lowest: $39.00 (Berenberg)
- Average: $77.25
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$77.25 (+149.8%)
* Over Last 12-Mos
Rating Score: 8.1 / 10
Percentile Rank: 83%
Avg. $ Target:
$77.25 (+149.8%)
* Over Last 12-Mos
Rating Score: 8.1 / 10
Percentile Rank: 83%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/23/2022 | Berenberg | Caroline Palomeque | New Coverage | Buy (N/A) |
39.00 (N/A) |
27.21 (30.93) |
13.67% | Details |
| 12/10/2021 | Raymond James | Danielle Brill | New Coverage | Market Perform (N/A) |
N/A (N/A) |
46.16 (30.93) |
-32.99% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
